Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
November 06, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results
October 31, 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast
October 17, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors
September 19, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
August 02, 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
— Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company’s third study of its FcRn inhibitor; top-line data expected by end of 2021 — —...
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
August 01, 2019 16:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)
July 30, 2019 07:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast
July 19, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation
June 19, 2019 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference
June 04, 2019 07:30 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat...